Vigafyde: Uses, Dosage, Side Effects, Warnings - Drugs.com
Jun 20, 2024 · Vigafyde (vigabatrin) is a ready-to-use oral solution that may be used to treat babies aged 1 month to 2 years of age with infantile spasms (IS) if the possible benefits of …
label - accessdata.fda.gov
VIGAFYDE is indicated as monotherapy for the treatment of infantile spasms in pediatric patients 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision...
Vigafyde (Vigabatrin Oral Solution): Side Effects, Uses ... - RxList
Jul 1, 2024 · VIGAFYDE is a prescription medicine used to treat babies 1 month to 2 years of age who have infantile spasms (IS) if you and your baby’s healthcare provider decide the …
DailyMed - VIGAFYDE- vigabatrin solution
Sep 23, 2025 · VIGAFYDE (vigabatrin) oral solution is an antiepileptic drug. The chemical name of vigabatrin is (±) 4-amino-5-hexenoic acid, a racemic mixture of R and S isomers.
VIGAFYDE™ - PANTHERx Rare
VIGAFYDE™ (vigabatrin) www.vigafyde.com Monotherapy for the treatment of infantile spasms in pediatric patients 1 month to 2 years of age for whom the potential benefits outweigh the …
Upsher-Smith’s Vigafyde
May 19, 2025 · VIGAFYDE™, the only ready-to-use vigabatrin oral solution, is the first new drug application (NDA) approved for infantile spasms in 15 years.
VIGAFYDE (Upsher-Smith Laboratories, LLC): FDA Package Insert
Sep 23, 2025 · Vision assessment is recommended at baseline (no later than 4 weeks after starting VIGAFYDE), at least every 3 months during therapy, and about 3 to 6 months after the …
Pyros Pharmaceuticals Announces VIGAFYDE™ (vigabatrin), the …
Sep 3, 2024 · VIGAFYDE™ is a ready-to-use vigabatrin oral solution indicated as monotherapy for the treatment of infantile spasms in pediatric patients 1 month to 2 years of age for whom …
New FDA Approval: VIGAFYDE™ (vigabatrin) Oral Solution
Jun 17, 2024 · VIGAFYDE™ is an anticonvulsant that works in the treatment of infantile spasms by inhibiting the enzyme, gamma-aminobutyric acid (GABA) transaminase, consequently …
VIGAFYDE - Upsher-Smith Laboratories, LLC
Sep 23, 2025 · Vision assessment is recommended at baseline (no later than 4 weeks after starting VIGAFYDE), at least every 3 months during therapy, and about 3 to 6 months after the …